Affordable Prescriptions for Patients Act of 2023

The Affordable Prescriptions for Patients Act of 2023 targets "product hopping" by pharmaceutical manufacturers, which occurs when companies discontinue an original drug to make way for a follow-on product and prevent competition from cheaper generics or biosimilars. The bill prohibits two types of anti-competitive conduct: "hard switches" (discontinuing a drug or withdrawing approval) and "soft switches" (taking actions to disadvantage the original drug relative to a follow-on product). It gives the Federal Trade Commission authority to enforce these rules, including seeking remedies like disgorgement of profits from anti-competitive behavior. This legislation directly affects drug manufacturers, particularly those producing reference drugs and follow-on products, with the goal of increasing competition in the pharmaceutical market and lowering prescription costs.